MTOR and breast carcinoma: In addition, PgR may in the long run be downregulated through PI3K/AKT/mTOR pathway stimulation and subsequent aberrant ER signalling, leading to acquired endocrine resistance among patients with initially ER/PgR-positive breast cancers.